Roche commits to lean-mass preservation with Hanmi obesity deal
BioPharma Dive
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
pharminent
August 24, 2026 (Last updated: August 25, 2026)
BioPharma Dive
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
